# Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration

> **NCT01014468** · PHASE3 · UNKNOWN · sponsor: **Instituto de Olhos de Goiania** · enrollment: 500 (actual)

## Conditions studied

- Age Related Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab (Intravitreal injection)
- **DRUG:** Bevacizumab (Intravitreal injection)

## Key facts

- **NCT ID:** NCT01014468
- **Lead sponsor:** Instituto de Olhos de Goiania
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-03
- **Primary completion:** 2009-11
- **Final completion:** 2012-02
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2011-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01014468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01014468, "Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01014468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*